219 related articles for article (PubMed ID: 26242222)
1. Pharmacokinetics and pharmacogenetics of capecitabine and its metabolites following replicate administration of two 500 mg tablet formulations.
Queckenberg C; Erlinghagen V; Baken BC; Van Os SH; Wargenau M; Kubeš V; Peroutka R; Novotný V; Fuhr U
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1081-91. PubMed ID: 26242222
[TBL] [Abstract][Full Text] [Related]
2. The role of pharmacogenetics in capecitabine efficacy and toxicity.
Lam SW; Guchelaar HJ; Boven E
Cancer Treat Rev; 2016 Nov; 50():9-22. PubMed ID: 27569869
[TBL] [Abstract][Full Text] [Related]
3. Bioactivation of capecitabine in human liver: involvement of the cytosolic enzyme on 5'-deoxy-5-fluorocytidine formation.
Tabata T; Katoh M; Tokudome S; Hosakawa M; Chiba K; Nakajima M; Yokoi T
Drug Metab Dispos; 2004 Jul; 32(7):762-7. PubMed ID: 15205393
[TBL] [Abstract][Full Text] [Related]
4. 5-Fluorouracil pharmacogenomics: still rocking after all these years?
Scartozzi M; Maccaroni E; Giampieri R; Pistelli M; Bittoni A; Del Prete M; Berardi R; Cascinu S
Pharmacogenomics; 2011 Feb; 12(2):251-65. PubMed ID: 21332317
[TBL] [Abstract][Full Text] [Related]
5. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients.
Sharma R; Hoskins JM; Rivory LP; Zucknick M; London R; Liddle C; Clarke SJ
Clin Cancer Res; 2008 Feb; 14(3):817-25. PubMed ID: 18245544
[TBL] [Abstract][Full Text] [Related]
6. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients.
Schüller J; Cassidy J; Dumont E; Roos B; Durston S; Banken L; Utoh M; Mori K; Weidekamm E; Reigner B
Cancer Chemother Pharmacol; 2000; 45(4):291-7. PubMed ID: 10755317
[TBL] [Abstract][Full Text] [Related]
7. Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients.
Cassidy J; Twelves C; Cameron D; Steward W; O'Byrne K; Jodrell D; Banken L; Goggin T; Jones D; Roos B; Bush E; Weidekamm E; Reigner B
Cancer Chemother Pharmacol; 1999; 44(6):453-60. PubMed ID: 10550565
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics of capecitabine in advanced breast cancer patients.
Largillier R; Etienne-Grimaldi MC; Formento JL; Ciccolini J; Nebbia JF; Ginot A; Francoual M; Renée N; Ferrero JM; Foa C; Namer M; Lacarelle B; Milano G
Clin Cancer Res; 2006 Sep; 12(18):5496-502. PubMed ID: 17000685
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine.
Roberto M; Romiti A; Botticelli A; Mazzuca F; Lionetto L; Gentile G; Paris I; Falcone R; Bassanelli M; Di Pietro FR; Onesti CE; Anselmi E; Macrini S; Simmaco M; Marchetti P
Eur J Clin Pharmacol; 2017 Feb; 73(2):157-164. PubMed ID: 27864592
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis.
Jacobs BAW; Deenen MJ; Joerger M; Rosing H; de Vries N; Meulendijks D; Cats A; Beijnen JH; Schellens JHM; Huitema ADR
CPT Pharmacometrics Syst Pharmacol; 2019 Dec; 8(12):940-950. PubMed ID: 31652031
[TBL] [Abstract][Full Text] [Related]
11. Predictive markers of capecitabine sensitivity identified from the expression profile of pyrimidine nucleoside-metabolizing enzymes.
Yasuno H; Kurasawa M; Yanagisawa M; Sato Y; Harada N; Mori K
Oncol Rep; 2013 Feb; 29(2):451-8. PubMed ID: 23229803
[TBL] [Abstract][Full Text] [Related]
12. Methylenetetrahydrofolate reductase C677T is not associated with expression of pyrimidine metabolic enzyme genes in colorectal cancer.
Takeda R; Kamano T; Sakamoto K; Sugano M; Hosoda S; Watanabe T; Maeda T; Kojima Y
J Int Med Res; 2006; 34(3):307-15. PubMed ID: 16866026
[TBL] [Abstract][Full Text] [Related]
13. CDA and MTHFR polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine-based chemotherapy.
Liu D; Li X; Li X; Zhang M; Zhang J; Hou D; Tong Z; Dong M
Cancer Chemother Pharmacol; 2019 May; 83(5):939-949. PubMed ID: 30877365
[TBL] [Abstract][Full Text] [Related]
14. Comparison of pharmacokinetics and safety profiles of two capecitabine tablet formulations in patients with colon, colorectal or breast cancer.
Chachad S; Purandare S; Malhotra G; Naidu R
Cancer Chemother Pharmacol; 2013 Feb; 71(2):287-92. PubMed ID: 23090620
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous determination of capecitabine and its three nucleoside metabolites in human plasma by high performance liquid chromatography-tandem mass spectrometry.
Deng P; Ji C; Dai X; Zhong D; Ding L; Chen X
J Chromatogr B Analyt Technol Biomed Life Sci; 2015 May; 989():71-9. PubMed ID: 25808944
[TBL] [Abstract][Full Text] [Related]
16. Assessment of pharmacokinetic variations of capecitabine after multiple administration in rats: a physiologically based pharmacokinetic model.
Sakai S; Kobuchi S; Ito Y; Sakaeda T
Cancer Chemother Pharmacol; 2020 May; 85(5):869-880. PubMed ID: 32240335
[TBL] [Abstract][Full Text] [Related]
17. Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients.
Kristensen MH; Pedersen PL; Melsen GV; Ellehauge J; Mejer J
J Int Med Res; 2010; 38(3):870-83. PubMed ID: 20819423
[TBL] [Abstract][Full Text] [Related]
18. Circadian variations in the pharmacokinetics of capecitabine and its metabolites in rats.
Kobuchi S; Yazaki Y; Ito Y; Sakaeda T
Eur J Pharm Sci; 2018 Jan; 112():152-158. PubMed ID: 29175408
[TBL] [Abstract][Full Text] [Related]
19. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy.
Joerger M; Huitema AD; Boot H; Cats A; Doodeman VD; Smits PH; Vainchtein L; Rosing H; Meijerman I; Zueger M; Meulendijks D; Cerny TD; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2015 Apr; 75(4):763-72. PubMed ID: 25677447
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity.
Loganayagam A; Arenas Hernandez M; Corrigan A; Fairbanks L; Lewis CM; Harper P; Maisey N; Ross P; Sanderson JD; Marinaki AM
Br J Cancer; 2013 Jun; 108(12):2505-15. PubMed ID: 23736036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]